BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF)
("
BriaCell" or the "
Company"), an
immuno-oncology focused biotechnology company with a proprietary
targeted immunotherapy technology, today announces it has been
selected to present a poster at the 2019 ASCO-SITC Clinical
Immuno-Oncology Symposium, held February 28–March 2, 2019, in San
Francisco, California. The poster will highlight findings related
to the mechanism of action of the Company’s lead candidate,
Bria-IMT™, to BriaDX™, the companion diagnostic test aimed at
helping identify those patients most likely to benefit from
Bria-IMT™, and to Bria-OTS™, BriaCell’s off-the-shelf personalized
immunotherapy. Additionally, Dr. Charles L. Wiseman, BriaCell’s
founder and director, will be a keynote speaker at the 10th Euro
Breast Cancer Summit, being held in Paris, France, March 20-21,
2019. Furthermore, BriaCell has also been accepted to present a
poster at the American Association for Cancer Research (AACR)
Annual Meeting being held March 29-April 3, 2019, at Georgia World
Congress Center, Atlanta, Georgia. The poster will summarize
molecular and clinical findings supporting the advancement of the
Bria-OTS™ program.
2019
ASCO-SITC Clinical Immuno-Oncology SymposiumSan
Francisco, CaliforniaFebruary 28–March 2,
2019
BriaCell will highlight important clinical and
molecular findings of its completed, 23-subject Phase I/IIa trial
of Bria-IMT™ in patients with advanced breast cancer, including
significant tumor regression in certain patients who matched
Bria-IMT™ at HLA types. Additionally, an analysis of immunologic
factors will be presented, including delayed-type hypersensitivity
and antibody responses suggesting heightened immune activity in
patients treated with Bria-IMT™. HLA-matching subjects had an
improved response rate (i.e., tumor reduction), and HLA matching is
currently being evaluated as a predictor of the tumor response in
the ongoing combination study of Bria-IMT™ with KEYTRUDA®
[manufactured by Merck & Co., Inc. (NYSE: MRK)], listed in
ClinicalTrials.gov as NCT03328026. These data support the Company’s
Bria-OTS™ program.
The details of the poster are as follows:
Abstract Submission ID:
245533Abstract Number: 6Title:
Targeted tumor-derived cellular immunotherapy in advanced breast
cancer patients induces initial immune responses and tumor
regression.Session Information: Poster Session
BDate: Friday, March 1, 2019,
Time: 11:30 a.m.–1:00 p.m.; 5:30 p.m. – 6:30 p.m.
PTLocation: Golden Gate
Hall, B2 LevelPoster Board Number: B4
Following the presentation, a copy of the poster will be posted
on http://briacell.com/investor-relations/presentations/.
10th Euro Breast Cancer
SummitParis, FranceMarch 20–21,
2019
Dr. Charles L. Wiseman will be a keynoter
speaker at the 10th Euro Breast Cancer Summit, being held in Paris,
France, March 20-21, 2019. This year’s theme will be “Rediscovering
Novel Approaches towards Cure for Breast Cancer and Women’s
Health”.
AACR Annual Meeting 2019
Atlanta, GeorgiaMarch 29–April 3,
2019
BriaCell will summarize efficacy and safety data
of its lead candidate, Bria-IMT™, as obtained in several clinical
trials. Additionally, insights into Bria-IMT™’s mechanism of action
will be provided, which are, in essence, molecular and clinical
findings supporting the development of Bria-OTS™, BriaCell’s
off-the-shelf personalized immunotherapy, program. Bria-OTS™
consists of a set of cell lines under development that are similar
to Bria-IMT™ but engineered to produce different human leukocyte
antigen (HLA) antigens to match individual patients. BriaCell
anticipates an increased response rate (i.e., tumor reduction) with
HLA-matched Bria-OTS™ cell lines compared to unmatched Bria-IMT™ in
advanced breast cancer patients. Bria-OTS™ is currently under
development, with plans to enter the clinic later in 2019.
The details of the poster are as follows:
Abstract Control
Number: 3662Title: Development
of a personalized off-the-shelf whole-cell immunotherapy for breast
cancerSession
Category: ImmunologySession
Title: Immunomodulators and Response to
TherapyDate: Wednesday, April 3, 2019
Time: 8:00 a.m.–12:00 p.m.
ETLocation: Georgia World Congress Center,
Exhibit Hall B, Poster Section 24Poster Board
Number: 21Permanent Abstract Number:
4998
Following the presentation, a copy of the poster will be posted
on http://briacell.com/investor-relations/presentations/.
“An estimated 42,000 women will die of breast
cancer in 2019 in the U.S. alone, indicating a substantial unmet
medical need for a large patient population whose tumors had become
resistant to chemotherapy or other therapeutic regimens. Currently,
there are no effective treatment options for these patients,
leaving them with a very poor prognosis and a grim survival
outlook,” stated Dr. Bill Williams, president and CEO of BriaCell.
“We are excited to share our findings with the scientific and
medical community at ASCO-SITC Clinical Immuno-Oncology Symposium
and the AACR meeting. We believe that our unique approach is
promising and supports personalizing our immunotherapy to match
individual patients. HLA typing may serve as a companion diagnostic
test, BriaDX™, to determine the best match for Bria-IMT™ and for
Bria-OTS™, our off-the-shelf personalized immunotherapy, which is
under development for breast cancer patients. Bria-OTS™ has the
potential to stimulate the immune system in a manner tailored to
the patient without the complexities associated with other
personalized therapies, to bring hope to advanced breast cancer
patients with few effective treatment options. Further studies are
merited and in progress, especially for our ongoing combination
study of Bria-IMT™ with KEYTRUDA®.”
Separately, the Company has posted a revamped
investor presentation along with more detailed investor and
scientific presentations on BriaCell’s website:
http://briacell.com/investor-relations/presentations/.
About
ASCO-SITC Clinical Immuno-Oncology Symposium
Designed for clinicians, scientists and all
other members of the cancer care and research community,
ASCO-SITC Clinical Immuno-Oncology Symposium is
a three-day meeting dedicated to clinical and translational
research and advancements in immuno-oncology and the
implications for clinical use and patient care. This
meeting focuses on clinical education in immuno-oncology where
all aspects of care are fundamentally different from traditional
therapies.
For more information on
ASCO-SITC Clinical Immuno-Oncology Symposium, please
visit: https://immunosym.org.
About Euro Breast Cancer
Summit
In its 10th year, the Euro Breast Cancer Summit
gathers cancer biologists, oncologists, pathologists and other
medical professionals to discuss the latest innovations in the
field of breast cancer.
This year’s theme will be “Rediscovering Novel
Approaches towards Cure for Breast Cancer and Women’s Health”.
For more information on Euro Breast Cancer Summit, please visit:
https://eurobreastcancer.cancersummit.org/organizing-committee.php.
About AACR
Founded in 1907 in Washington, D.C., May 7,
1907, by a group of 11 physicians and scientists intended “to
further the investigation and spread the knowledge of cancer”, to
prevent and cure cancer using research, education, communication,
collaboration, funding, and advocacy have been the mission of AACR.
With its programs and services, AACR advances research in cancer
and related biomedical science by facilitating exchange of
knowledge and innovations among scientists and clinicians dedicated
to the fight against cancer, providing education and training in
oncology treatment and advancing cancer etiology, prevention, early
detection, diagnosis and treatment worldwide.
For more information on AACR, please
visit: https://www.aacr.org.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and safe approaches for
the management of cancer.
BriaCell is currently conducting a Phase I/IIa
clinical trial of Bria-IMT™, its lead candidate, in a combination
study with pembrolizumab (KEYTRUDA®; manufactured by Merck &
Co., Inc.). The combination study is listed in ClinicalTrials.gov
as NCT03328026.
BriaCell is developing Bria-OTS™, an
off-the-shelf personalized immunotherapy, for advanced breast
cancer. Bria-OTS™ immunotherapy treatments are personalized to
match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 90 percent of the
patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while
eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please
visit: http://www.BriaCell.com.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024